BCRX
Price
$7.83
Change
-$0.01 (-0.13%)
Updated
Dec 4, 04:59 PM (EDT)
Capitalization
1.65B
83 days until earnings call
Intraday BUY SELL Signals
HOWL
Price
$0.99
Change
+$0.07 (+7.61%)
Updated
Dec 4, 04:59 PM (EDT)
Capitalization
44.51M
105 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BCRX vs HOWL

Header iconBCRX vs HOWL Comparison
Open Charts BCRX vs HOWLBanner chart's image
BioCryst Pharmaceuticals
Price$7.83
Change-$0.01 (-0.13%)
Volume$103.35K
Capitalization1.65B
Werewolf Therapeutics
Price$0.99
Change+$0.07 (+7.61%)
Volume$5.16K
Capitalization44.51M
BCRX vs HOWL Comparison Chart in %
View a ticker or compare two or three
VS
BCRX vs. HOWL commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCRX is a StrongBuy and HOWL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (BCRX: $7.85 vs. HOWL: $0.92)
Brand notoriety: BCRX: Notable vs. HOWL: Not notable
BCRX represents the Pharmaceuticals: Generic, while HOWL is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCRX: 137% vs. HOWL: 67%
Market capitalization -- BCRX: $1.65B vs. HOWL: $44.51M
BCRX [@Pharmaceuticals: Generic] is valued at $1.65B. HOWL’s [@Biotechnology] market capitalization is $44.51M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $117.5B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.24B. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCRX’s FA Score shows that 1 FA rating(s) are green whileHOWL’s FA Score has 1 green FA rating(s).

  • BCRX’s FA Score: 1 green, 4 red.
  • HOWL’s FA Score: 1 green, 4 red.
According to our system of comparison, both BCRX and HOWL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCRX’s TA Score shows that 5 TA indicator(s) are bullish while HOWL’s TA Score has 6 bullish TA indicator(s).

  • BCRX’s TA Score: 5 bullish, 4 bearish.
  • HOWL’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, HOWL is a better buy in the short-term than BCRX.

Price Growth

BCRX (@Pharmaceuticals: Generic) experienced а +10.56% price change this week, while HOWL (@Biotechnology) price change was -6.05% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.59%. For the same industry, the average monthly price growth was +0.46%, and the average quarterly price growth was +18.84%.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.75%. For the same industry, the average monthly price growth was +5.41%, and the average quarterly price growth was +55.63%.

Reported Earning Dates

BCRX is expected to report earnings on Feb 25, 2026.

HOWL is expected to report earnings on Mar 19, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.59% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

@Biotechnology (+0.75% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BCRX($1.65B) has a higher market cap than HOWL($44.5M). BCRX YTD gains are higher at: 4.388 vs. HOWL (-37.980). BCRX has higher annual earnings (EBITDA): 63.4M vs. HOWL (-66.34M). BCRX has more cash in the bank: 260M vs. HOWL (77.6M). HOWL has less debt than BCRX: HOWL (37.1M) vs BCRX (703M). BCRX has higher revenues than HOWL: BCRX (558M) vs HOWL (0).
BCRXHOWLBCRX / HOWL
Capitalization1.65B44.5M3,717%
EBITDA63.4M-66.34M-96%
Gain YTD4.388-37.980-12%
P/E RatioN/AN/A-
Revenue558M0-
Total Cash260M77.6M335%
Total Debt703M37.1M1,895%
FUNDAMENTALS RATINGS
BCRX: Fundamental Ratings
BCRX
OUTLOOK RATING
1..100
8
VALUATION
overvalued / fair valued / undervalued
1..100
33
Fair valued
PROFIT vs RISK RATING
1..100
81
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
78
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BCRXHOWL
RSI
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
72%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
75%
MACD
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 7 days ago
81%
Declines
ODDS (%)
Bearish Trend 11 days ago
80%
Bearish Trend 21 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
Aroon
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
BCRX
Daily Signal:
Gain/Loss:
HOWL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MREO1.960.21
+12.00%
Mereo BioPharma Group plc
SPCB9.310.23
+2.59%
SuperCom Ltd
CGEAF46.02N/A
N/A
Cogeco Communications Inc
SFOSF3.30N/A
N/A
Shanghai Fosun Pharmaceutical Group Co Ltd
NVRI18.29-0.01
-0.05%
Enviri Corp

BCRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCRX has been loosely correlated with VCYT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if BCRX jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCRX
1D Price
Change %
BCRX100%
+9.64%
VCYT - BCRX
46%
Loosely correlated
+3.44%
CRNX - BCRX
42%
Loosely correlated
+4.38%
HOWL - BCRX
39%
Loosely correlated
+6.73%
ROIV - BCRX
38%
Loosely correlated
+2.99%
BEAM - BCRX
38%
Loosely correlated
+14.42%
More

HOWL and

Correlation & Price change

A.I.dvisor indicates that over the last year, HOWL has been loosely correlated with CRBU. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if HOWL jumps, then CRBU could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HOWL
1D Price
Change %
HOWL100%
+6.73%
CRBU - HOWL
43%
Loosely correlated
+5.68%
IPSC - HOWL
41%
Loosely correlated
-3.63%
ALGS - HOWL
41%
Loosely correlated
+7.17%
RXRX - HOWL
40%
Loosely correlated
+7.87%
ATNM - HOWL
40%
Loosely correlated
+5.07%
More